Background: The GeparQuattro study showed that adding capecitabine or prolonging the duration of anthracyclinetaxane-based neoadjuvant chemotherapy from 24 to 36 weeks did not increase pathological complete response ( pCR) rates. Trastuzumab-treated patients with HER2-positive disease showed a higher pCR rate than patients with HER2-negative disease treated with chemotherapy alone. We here present disease-free (DFS) and overall survival (OS) analyses.
introduction
Pathological complete response ( pCR) after neoadjuvant chemotherapy has been considered as a precisely assessable predictor for disease-free (DFS) and overall survival (OS) in patients with primary breast cancer [1] [2] [3] . However, the large GeparTrio trial showed no improvement in pCR rates, but showed a survival advantage for the experimental treatments [4] . This demonstrates the importance to confirm the finding on pCR with corresponding survival analyses.
The GeparQuattro study (clinical trial.gov NCT 00288002) is a phase III neoadjuvant study exploring the addition of capecitabine and trastuzumab to EC-T chemotherapy. Capecitabine was given in one experimental arm simultaneously to docetaxel (Taxotere) and in another experimental arm in sequence to docetaxel, so that the trial could examine the effect of capecitabine as well as a 24 weeks treatment with a 36 weeks treatment. We have previously reported that EC-T with and without capecitabine as well as shorter and longer treatment resulted in similar pCR rates of in average 18.7% (ypT0 ypN0) or 25.8% (ypT0/is ypN0) [5] . The addition of trastuzumab was investigated as a second primary end point by an indirect comparison of patients with HER2-positive disease when treated in addition to trastuzumab with a reference group of patients with HER2-negative tumors treated with chemotherapy alone in the same study. This indirect comparison was considered acceptable as previous reports did not show different pCR rates for HER2-positive and HER2-negative disease when treated with anthracyclines and taxanes [6] . The results showed a pCR rate of 29.0% (ypT0 ypN0) or 41.4% (ypT0/is ypN0) for the HER2-positive/trastuzumab-treated patients and a pCR rate of 13.2% (ypT0 ypN0) or 17.8% (ypT0/is ypN0) for the HER2-negative/not-trastuzumabtreated patients [7] . We here report the corresponding survival analyses.
patients and methods objectives
The primary efficacy end point of the study was pathological complete response ( pCR) and has been reported together with the related toxicity earlier [8] [5] . Similar comparisons of treatments were planned as secondary objective of the study for DFS and OS as end points. Long-term cardiac assessment continued during follow-up.
selection of patients
Female patients with previously untreated, unilateral or bilateral primary breast carcinoma were enrolled in the study if they provided a written informed consent. Tumor lesions needed to have a palpable size of ≥2 cm or a sonographical size of ≥1 cm in diameter. Locally advanced tumors with cT4 or cT3; or estrogen-(ER) and progesterone-(PgR) receptor-negative tumors; or ER or PgR positive tumors which are cN+ (for cT2) or pNSLN+ (for cT1) were eligible. Further eligibility criteria have been described previously [8] .
treatment
All patients were scheduled to four cycles of EC (epirubicin 90 mg/m 2 , cyclophosphamide 600 mg/m 2 , all on day 1, every 3 weeks). Thereafter, patients were randomly assigned to either docetaxel (Taxotere) 100 mg/m² day 1 q day 21 for four cycles (EC-T), or docetaxel 75 mg/m² day 1 q day 21 for four cycles plus capecitabine 900 mg/m² twice daily days 1-14 q day 21 for four cycles (EC-TX), or docetaxel 75 mg/m² day 1 q day 21 for four cycles followed by capecitabine 900 mg/m² twice daily days 1-14 q day 21 for four cycles (EC-T-X). Patients with HER2-positive tumors received trastuzumab 6 mg/kg i.v. every 3 weeks concomitantly to all cytotoxic treatment, starting with a loading dose of 8 mg/kg i.v. on day 1 of the first EC cycle. Recommended postoperative treatment consisted of radiotherapy to the ipsilateral remaining breast for all patients treated by breast-conserving surgery and radiotherapy to the chest wall with or without regional nodes in case of mastectomy for patients with an initial tumor size of >5 cm or clinically suspect axillary nodes before treatment or histologically involved nodes after neoadjuvant treatment. Endocrine treatment was given for at least 5 years in patients with ER-and/or PgR-positive tumors, and trastuzumab treatment was completed for a total duration of 12 months in patients with HER2-positive disease. Six monthly visits or telephone contacts were scheduled for at least 5 years to collect information on disease status. Patients with residual tumors at surgery were allowed to participate in a post-neoadjuvant randomized study on zoledronate or observation (NeoAdjuvant-Trial-Add-oN [NaTaN]) (NCT00512993) [9] .
assessment of end points DFS (invasive) was calculated as the time from study registration to any invasive locoregional, contralateral or distant recurrence of breast cancer or any second primary invasive non-breast cancer or death of a patient due to any cause and OS to death of any cause [10] . During neoadjuvant chemotherapy local progression of the breast tumor was not considered as a relapse. Postprogression survival was calculated as time from first relapse to death. Response to neoadjuvant treatment was assessed clinically after four cycles of chemotherapy and before surgery as described previously [8] .
Pathological response was assessed locally by examining all surgically excised breast and axillary lymphatic tissue according to the tumour-nodemetastasis classification. Pathology reports were centrally reviewed at German Breast Group headquarters.
Information on cardiac toxicity was collected in parallel. However, no standardized cardiac monitoring during follow-up was foreseen in the protocol.
statistics
The GeparQuattro study was an open-label, randomized, phase III trial with two primary objectives. Allocation to capecitabine and chemotherapy duration was carried out by central randomization with a 1:1:1 ratio for the three chemotherapy treatments and a stratification according to the participating site, clinical response after four cycles of EC, HER2-status, ER/PgRstatus and disease stage. Allocation to trastuzumab was based on local HER2 status assessment of the breast tumor. Assumptions for sample size calculation have published previously [8] .
All analyses were carried out on an intent-to-treat approach including all patients having received one cycle chemotherapy and/or trastuzumab in the analysis for trastuzumab by HER2 status; and all patients randomly assigned after four cycles of EC in the capecitabine and duration analyses (CONSORT statement).
Survival analysis was planned after median follow up of five years. Time to event outcome parameters were estimated using the Kaplan-Meier product-limit method and treatment groups were compared using the log-rank test. Univariate Cox proportional hazards models were used to calculate hazard ratios (HRs); 95% confidence intervals (CI) are provided. Multivariate Cox model was used to adjust for relevant baseline characteristics. Univariate Cox model was carried out in predefined subgroups similar to those used for the analysis of the pCR primary end point [9] and Cox model including interaction between subgroup factor and therapy was used to test for heterogeneity across subgroups. All statistical tests were two-sided by default; the significance level was set to 0.05 unadjusted for multiple comparisons.
results
Between August 2005 and December 2006, 1495 patients were registered in the study and started neoadjuvant treatment (CONSORT statement). After completion of chemotherapy and surgery, 1408 patients were followed up for a median of 5.4 years until November 9th, 2012. Forty patients died without relapse of disease. Baseline characteristics of patients were well balanced between treatment groups as previously shown [1, 2] . DFS and OS were similar for patients treated with the three different chemotherapy regimens (Figure 1 ). There was no statistically significant difference in survival for patients receiving capecitabine or not together with or after anthracycline-taxane based chemotherapy (P = 0.463 for DFS and P = 0.618 for OS). Similarly there was no difference in outcome for patients receiving 24 weeks or 36 weeks of chemotherapy (P = 0.818 for DFS and P = 0.825 for OS). A multivariate analysis (Table 1) (Figure 2 ) could not identify a subgroup for which an effect of capecitabine on DFS might be postulated. Patients with hormone-receptor-positive tumors showed the lowest hazard ratio of 0.8 with an upper CI of 1.09 marginally crossing one in favor of adding capecitabine (test for interaction P = 0.832). Similarly no subgroup according to conventional risk factors was found favoring 24 or 36 weeks of chemotherapy duration.
Comparing DFS and OS in patients having HER2-positive tumors and being treated with chemotherapy plus trastuzumab with patients having HER2-negative tumors and being treated with chemotherapy alone, no statistically significant difference was found (P = 0.305 for DFS and P = 0.074 for OS) (Figure 3) . The baseline-factor adjusted survival analysis revealed a HR of 0.83 (P = 0.145) for DFS and a HR of 0.70 (P = 0.040) for OS in favor of the HER2-positive/trastuzumab-treated group ( Table 1) . As for the HER2-positive/trastuzumab-treated group a better outcome was observed only for OS but not for DFS, we compared in a post-hoc analysis post-progression survival between the two groups for those patients with documented relapse. In fact, post-progression survival was significantly better (P = 0.039) for relapsed patients with HER2-positive tumors compared with relapsed patients with HER2-negative tumors (data not shown). Subgroup analysis (Figure 2 ) shows that patients with grade 3 tumors (HR 0.64; test for interaction P = 0.1044) or hormone-receptor-negative tumors (HR 0.66; test for interaction P = 0.0969) had a trend for better DFS when the tumor was HER2-positive and treated with trastuzumab compared with patients with HER2-negative tumors. During the current observation period cardiac events were reported for 9 (2.0%) patients receiving trastuzumab in concurrence to EC-T and in 26 (2.5%) patients receiving EC-T alone (congestive heart failure (0 versus 3), cardiac ischemia (3 versus 3), rhythm disorders (4 versus 14) and other cardiac events (2 versus 6)).
As the comparison of clinical response after four cycles EC and clinical response as well as histopathological response at surgery was a predefined end point, we also analyzed the prognostic information of these three methods of response evaluation (Figure 4) . Clinically complete response, partial remission or no change, and tumor progression after four treatment cycles resulted in different DFS (P ≤ 0.0001) ( Figure 4A ). By assessing clinical response at surgery, patients with complete response or with tumor progression showed a long-term prognosis comparable to the earlier assessment. In addition, DFS of patients with a partial remission appeared more favorable compared with patients with no change in clinical tumor size ( Figure 4B ). In fact, DFS according to the histological tumor stage at surgery shows a similar separation with patients having a pCR (ypT0/is ypN0) showing the best prognosis and patients with gross residual disease (ypT3 or ypT4) showing 5 year event rates of 55% and higher. However, the frequency of patients with complete remission increased over the assessment time points (n = 98 (6.7%) with cCR after 4 cycles EC, n = 347 (24.5%) with cCR at surgery, n = 424 (30.4%) with pCR) ( Figure 4C ).
discussion
Survival analysis confirmed the findings on pCR rates of the various treatments of the GeparQuattro study. No difference in DFS and OS was found for the neoadjuvant chemotherapy arms with or without capecitabine as well as for 24 weeks and 36 weeks of treatment duration. The only subgroup with a trend towards better outcome by the addition of capecitabine was the one with hormone-receptor-positive disease.
The results are in concordance with other capecitabine trials conducted in the adjuvant setting. The USON 01062 trial added capecitabine to AC-T given at identical doses and reported no increase in DFS after the statistical plan was changed from an event-driven to a time-driven analysis due to a low event rate [3] . However, a significant advantage for OS was observed which has to be interpreted with caution, given the lowered event rate and power of study. The Finish Breast Group compared docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) with the same regimen but simultaneous use of capecitabine with docetaxel and with 5-fluorouracil/epirubicin [11] . A HR of 0.66 in favor of the capecitabine arm had been observed in a 3-year interim analysis [12] . However, the final analysis showed a nonsignificant HR of 0.79 between arms [7] . A recent metaanalysis that combined both studies showed significantly improved survival for the addition of capecitabine at a HR of 0.83 (0.71;0.98) [8] .
The addition of trastuzumab to neoadjuvant chemotherapy and the postsurgical phase lead to a similar DFS of patients with HER2-positive disease when compared with a reference group of patients with HER2-negative disease receiving chemotherapy alone in the same study. As the natural course of HER2-positive disease is worse than HER2-negative disease, this could be interpreted as an improvement in outcomes. Comparison of OS revealed a significantly higher adjusted survival probability for patients with HER2-positive disease. However, it is likely that this effect at least in part derived from palliative treatment as post-progression survival was significantly more favorable in the HER2-positive subgroup. Surrogacy of pCR for survival cannot be adequately addressed in the GeparQuattro study due to the very different tumor biology and patient management of HER2-positive and negative diseases. However, the results correspond to findings of the Neoadjuvant Herceptin study [5] , where 118 trastuzumab untreated HER2-positive patients showed a worse event-free survival compared with 99 HER2-negative patients treated with the same chemotherapy in the same trial. As patients with HER2-positive tumors were randomly treated with trastuzumab, the effect of trastuzumab on pCR and survival could be precisely described and HER2-positive/trastuzumabtreated patients showed a better event-free survival than HER2-negative/not-trastuzumab-treated patients.
Analyses of the GeparQuattro study have several limitations: the three-arm design makes interpretation of data highly complex. Especially the comparison of trastuzumab-treated patients with HER2-positive disease with the reference group of patients with HER2-negative disease should be interpreted with caution due to the non-randomized, indirect type of analysis. Similar to the USON [8] and FINXX [13] study, the GeparQuattro study design used different doses of docetaxel in the control and experimental arms, so that the assessment of the capecitabine effect is biased by a potentially lower efficacy of docetaxel in the experimental arms [13] . Not randomizing 41 patients without response to EC might somewhat select a more favorable group of patients for the chemotherapy comparison. Finally, left ventricular ejection fraction measurement stopped before surgery, so that cardiac toxicity might be underestimated.
In conclusion, the results of the GeparQuattro study do not support the use of capecitabine in the neoadjuvant setting in addition to an anthracycline-taxane-based chemotherapy. However, the results support a sustained patient's benefit of trastuzumab when given together with neoadjuvant chemotherapy.
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